Euroopa Liit - eesti - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - chondrogenic põhjustatud hobuste allogeense perifeerse vere-tuletatud mesenchymal tüvirakkude - muud lihas-skeleti süsteemi häirete ravimid - hobused - vähendada kerge kuni mõõduka korduva lonkamine seotud mitte-septiline liigesepõletik hobused.

Eesti - eesti - Ravimiamet

berlimed s.a. - iloprost - infusioonilahuse kontsentraat - 10mcg 0.5ml 0.5ml 5tk

Eesti - eesti - Ravimiamet

schering ag - iloprost - infusioonilahuse kontsentraat - 100mcg 1ml 1ml 1tk

Eesti - eesti - Ravimiamet

berlimed s.a. - iloprost - infusioonilahus - 20mcg 1ml 1ml 5tk

Eesti - eesti - Ravimiamet

schering ag - iloprost - infusioonilahuse kontsentraat - 10mcg 0.5ml 0.5ml 5tk

Eesti - eesti - Ravimiamet

berlimed s.a. - iloprost - infusioonilahuse kontsentraat - 50mcg 0.5ml 0.5ml 1tk

Eesti - eesti - Ravimiamet

schering ag - iloprost - infusioonilahus - 20mcg 1ml 1ml 5tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

esteve pharmaceuticals gmbh - tiotepa - hematopoietic stem cell transplantation; neoplasms - antineoplastilised ained - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited  - onasemnogene abeparvovec - lihase atroofia, spinaalne - muud lihas-skeleti süsteemi häirete ravimid - zolgensma on näidustatud ravi:patsiendid, kellel on 5q seljaaju lihaste atroofia (sma) koos bi-allelic mutatsioon smn1 geeni-ja kliinilise diagnoosi akti liik 1, orpatients koos 5q sma koos bi-allelic mutatsioon smn1 geeni-ja kuni 3 koopiad smn2 geenide.

Euroopa Liit - eesti - EMA (European Medicines Agency)

instituto grifols s.a. - inimese normaalne immunoglobuliin - mucocutaneous lymph node syndrome; guillain-barre syndrome; bone marrow transplantation; purpura, thrombocytopenic, idiopathic; immunologic deficiency syndromes - suguhormoonid ja immunoglobuliinid, - replacement therapy in adults, children and adolescents (0-18 years) in: , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (hsct);, congenital aids with recurrent bacterial infections. , immunomodulation in adults, children and adolescents (0-18 years) in: , primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, guillain barré syndrome;, kawasaki disease.